Development of a Brain-Penetrant Nurr1 Agonist Tool

  • ChemMedChem. 2026 Jun 15;21(11):e70296. doi: 10.1002/cmdc.70296.
Jan Vietor  1 ,  Tanja Stiller  1 ,  Christian Gege  2 ,  Wael Saeb  3 ,  Úrsula López-García  1 ,  Hella Kohlhof  2 ,  Daniel Vitt  2 ,  Daniel Merk  1
Affiliations
  • 1. Department of Pharmacy, Ludwig-Maximilians-Universität München, Munich, Germany.
  • 2. Immunic AG, Gräfelfing, Germany.
  • 3. RebisLab R&D GmbH, Planegg-Martinsried, Germany.
Abstract

The ligand-sensing transcription factor nuclear receptor-related 1 (Nurr1), is thought to mediate neuroprotective activity and is implicated in various neurodegenerative diseases. Nurr1 ligands have been developed as tools to capture the receptor's potential in vitro and in vivo, but a dedicated brain-targeting agonist has been lacking. Here, we employed the scaffold of the Dihydroorotate Dehydrogenase (DHODH) inhibitor and strong Nurr1 activator vidofludimus to develop a descendant with a high brain-to-blood ratio. Scaffold-hopping from cyclopentene to thiophene, enhanced fluorination, and replacement of the carboxylic acid by an amide provided a highly potent, selective, and brain-penetrant Nurr1 agonist to study the effects of Nurr1 activation in the central nervous system (CNS).

Keywords
NR4A; blood‐brain‐barrier; nuclear receptor‐related 1; transcription factor.
Products